Peter Bräutigam, CEO and co-founder.
Mr. Bräutigam has over 40 years’ experience in the diagnostics and blood sampling business with executive positions at Roche Diagnostics, Sarstedt, Syva-Behring-Dade and Becton Dickinson . He is the founder of several companies active in the laboratory medicine area and has served as chairman for the Swedish laboratory technology association.
Dr. Ohlander has 10 years experience of applied research within the Fraunhofer Gesellschaft, Germanys largest application-oriented research organization. During her time in the Flexible Electronics group at the Fraunhofer EMFT in Munich, she worked on national and international industry oriented research projects and aqcuired a PhD from the KTH Royal Institute of Technology, Sweden. Her research expertise is in integrated foil-based sensors systems, roll-to-roll manufacturing, microfluidics and lab-on-chips.
Hans Peter Starck-Johnson
Senior Product Manager
Mr. Starck-Johnson has over 20 years of experience of R&D and product system design. For the last 15 years, focus has been on regulated medical and in vitro device technology at different managing positions, working with the whole chain from conceptualization to manufacturing, most recently as Director of device development at Aerocrine / Circassia, a company with successful sales of medical devices globally. Mr. Starck-Johnson holds several patents and has a MSc degree in Engineering physics from Chalmers University of Technology.
Board of Directors
PhD, CSO and co-founder
Dr. Beck is a Professor at the Karolinska Institute, Sweden and the head of the Pharmacology lab, Karolinska university hospital. Dr. Beck is a renown scientist in the Bioanalysis field and a pioneer of alternative sampling technologies reaching from human breath sampling to capillary blood sampling. He is the initiator and co-inventor of the Capitainer technology and founder of several start-up companies in patient sampling. Dr. Beck has published over 250 scientific articles in the field of chemical analysis.
Mr Bergryd has been active in the health care sector for over 40 years, both in international companies as well as private enterprises. He has been working in several positions in sales, marketing, medical affairs and general management. With his long business experience in fields of pharmaceuticals, medical device technology and medical diagnostics, Mr Bergryd adds key competence to take the Capitainer technology to the market.
CTO and co-founder
Mr. Lenk received his MSc degree in microsystem technology from IMTEK at the University of Freiburg, Germany. Mr. Lenk is co-inventor of the Capitainer device and currently pursuing a PhD at KTH Royal Institute of Technology, Sweden.
PhD, President R&D and co- founder
Dr. Roxhed is an Associate Professor in medical micro and nanosystems at KTH, Sweden and a research fellow of the Langer lab, Massachusetts Institute of Technology, Boston, USA. He is the initiator and co-inventor of the Capitainer device and has worked with several start-up companies, licensing of IP to the medtech industry and Fortune 100-companies. His research expertise is in MEMS technology, MEMS-based drug delivery and microfluidics for medical applications. He has co-authored more than 75 scientific papers and 8 patents.
Dr. Stemme is a Professor and head of the Micro and Nanosystem department of KTH, Sweden. His research on micro and nanotechnology, medical technology, microfluidics, optical applications, wafer-level packaging and device integration. Some of the results have successfully been commercialized. Dr. Stemme is co-inventor of the Capitainer technology, inventor of more than 30 patents and has co-authored more than 350 papers. He is a member of the Royal Swedish Academy of Sciences (KVA) and an IEEE Fellow.
Chairman of the Board
Ernst Westman is a civil engineer in chemical engineering with a specialization in medical molecular biology. He has been President and CEO of Boule Diagnostics AB from 1994 to March 31, 2017, where he built and led a world-leading listed company within decentralized blood cell counting to a market capitalization of SEK 1.5 billion. Prior to that, he has had several leading positions within companies’ active in life science and medical diagnostics.
Lars L Gustafsson
Dr Gustafsson is professor in clinical pharmacology at Karolinska Institutet in Stockholm. His research, teaching and clinical services have been focused on Rational Use of Medicines. As scientific and executive leader for numerous projects develop and implement new diagnostic, drug analytical and IT-based tools for optimal drug therapy. Experienced researcher in tropical clinical pharmacology and applying dried blood spot technology for drug monitoring. Now serves as Chair for the global IUPHAR (International Union of Pharmacology and Clinical Pharmacology) Subcommittee for clinical pharmacology in developing countries.
Dr Rydén is an Associate Professor in clinical chemistry at Linköping University. He has worked 8 years as the head of a clinical chemistry lab network in South-East of Sweden, and nearly 7 years as senior medical advisor at Roche Diagnostics. He is a co-inventor of novel diagnostic assays and co-founder of startup companies within laboratory diagnostics and life sciences. He has served as a board member in several companies, and has also served as chairman for the Swedish Society of Clinical Chemistry.